

Kevin Larimore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4188237/publications.pdf>

Version: 2024-02-01

8
papers

269
citations

1307594

7
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

263
citing authors

#	ARTICLE	IF	CITATIONS
1	Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). <i>Molecular Genetics and Metabolism</i> , 2018, 124, 27-38.	1.1	123
2	Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. <i>EBioMedicine</i> , 2018, 37, 366-373.	6.1	58
3	Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 108.	2.7	25
4	Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 217-227.	1.1	21
5	Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up. <i>Molecular Genetics and Metabolism</i> , 2020, 130, 239-246.	1.1	21
6	Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity. <i>Journal of Immunological Methods</i> , 2019, 468, 20-28.	1.4	9
7	Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria. <i>Clinical and Translational Science</i> , 2021, 14, 1894-1905.	3.1	8
8	Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses. <i>Molecular Genetics and Metabolism</i> , 2021, 134, 235-242.	1.1	4